EW - Edwards Lifesciences: TAVR And TMTT Strengths Key Growth Levers

• Edwards Lifesciences presents with the economic pillars that round out a robust investment case.
• Central to the sell-side's thesis is EW's valuation, which we firmly believe is justified at 46X earnings and 36X EBITDA.
• EW isn't the same business it was 2 or even 5 years ago, therefore assessing this name on historical valuation overlooks the future.
• Q1 sales performance serves as a good indicator of full-year expectations.
• Here, we cover all of the moving parts in the investment debate for the benefit of investors' own reasoning.

For further details see: